Compare CING & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CING | TVGN |
|---|---|---|
| Founded | 2012 | 2020 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.3M | 63.9M |
| IPO Year | N/A | N/A |
| Metric | CING | TVGN |
|---|---|---|
| Price | $4.98 | $10.60 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $34.50 | N/A |
| AVG Volume (30 Days) | ★ 750.7K | 40.1K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.16 | $0.14 |
| 52 Week High | $11.89 | $12.00 |
| Indicator | CING | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.24 | 60.04 |
| Support Level | $4.69 | $0.39 |
| Resistance Level | $5.35 | $12.00 |
| Average True Range (ATR) | 0.61 | 1.64 |
| MACD | 0.13 | 0.16 |
| Stochastic Oscillator | 90.20 | 84.10 |
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.